These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 26554923)

  • 1. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
    Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
    PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer.
    Uneno Y; Imura H; Makuuchi Y; Tochitani K; Watanabe N
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013604. PubMed ID: 36440894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-emptive diagnosis and treatment of fungal infections--evaluation of a single-centre policy.
    Schneider T; Halter J; Heim D; Passweg J; Stern M; Tichelli A; Weisser M; Gerull S
    Clin Microbiol Infect; 2012 Feb; 18(2):189-94. PubMed ID: 21729194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, Associazione Italiana Ematologia ed Oncologia Pediatrica, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Sorveglianza Epidemiologica delle Infezioni Fungine nelle Emopatie Maligne.
    Girmenia C; Aversa F; Busca A; Candoni A; Cesaro S; Luppi M; Pagano L; Rossi G; Venditti A; Nosari AM; ; ; ; ;
    Hematol Oncol; 2013 Sep; 31(3):117-26. PubMed ID: 23037867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation.
    Heimann SM; Vehreschild MJ; Cornely OA; Franke B; von Bergwelt-Baildon M; Wisplinghoff H; Kron F; Scheid C; Vehreschild JJ
    Eur J Haematol; 2015 Jun; 94(6):526-31. PubMed ID: 25310918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal pre-emptive strategy for high-risk neutropenic patients: why the story is still ongoing.
    Cordonnier C; Robin C; Alanio A; Bretagne S
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():27-35. PubMed ID: 24283975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial.
    Santolaya ME; Alvarez AM; Acuña M; Avilés CL; Salgado C; Tordecilla J; Varas M; Venegas M; Villarroel M; Zubieta M; Farfán M; de la Maza V; Vergara A; Valenzuela R; Torres JP
    J Antimicrob Chemother; 2018 Oct; 73(10):2860-2866. PubMed ID: 30010931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK.
    Ceesay MM; Sadique Z; Harris R; Ehrlich A; Adams EJ; Pagliuca A
    J Antimicrob Chemother; 2015 Apr; 70(4):1175-81. PubMed ID: 25535218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project.
    Pagano L; Caira M; Nosari A; Cattaneo C; Fanci R; Bonini A; Vianelli N; Garzia MG; Mancinelli M; Tosti ME; Tumbarello M; Viale P; Aversa F; Rossi G;
    Haematologica; 2011 Sep; 96(9):1366-70. PubMed ID: 21565903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.
    Tan BH; Low JG; Chlebicka NL; Kurup A; Cheah FK; Lin RT; Goh YT; Wong GC
    Int J Infect Dis; 2011 May; 15(5):e350-6. PubMed ID: 21397541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review on efficacy and safety of empirical versus pre-emptive antifungal therapy among children with febrile neutropenia reveals paucity of data.
    Sachdeva M; Malik M; Pradhan P; Kaur K; Dogra S; Mathew JL
    Mycoses; 2024 Apr; 67(4):e13722. PubMed ID: 38606896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis.
    Goldberg E; Gafter-Gvili A; Robenshtok E; Leibovici L; Paul M
    Eur J Cancer; 2008 Oct; 44(15):2192-203. PubMed ID: 18706808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease.
    Freemantle N; Tharmanathan P; Herbrecht R
    J Antimicrob Chemother; 2011 Jan; 66 Suppl 1():i25-35. PubMed ID: 21177401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
    Barnes R; Earnshaw S; Herbrecht R; Morrissey O; Slavin M; Bow E; McDade C; Charbonneau C; Weinstein D; Kantecki M; Schlamm H; Maertens J
    Clin Ther; 2015 Jun; 37(6):1317-1328.e2. PubMed ID: 25891805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
    Rogers TR; Slavin MA; Donnelly JP
    Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mycoses and their treatment in malignant hemopathies].
    Martino P; Girmenia C
    Recenti Prog Med; 1999 Mar; 90(3):160-8. PubMed ID: 10228357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
    Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.